Durect Corporation is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products. Its primary objective is to address pressing medical needs through innovation in pain management, central nervous system diseases, and other chronic conditions. Key features of Durect's portfolio include extended-release drug delivery technologies and novel pharmaceutical agents. One of its notable products is an investigational post-surgical pain management system that aims to enhance patient recovery and pain relief. The company actively engages in collaborations with other pharmaceuticals to leverage synergies in drug development and distribution. In the financial market, Durect Corporation stands out for its commitment to improving therapeutic outcomes and optimizing drug administration. Its contributions cater primarily to healthcare sectors that focus on improving patient quality of life and reducing healthcare costs associated with long-term treatment strategies. Founded in 1998 and based in Cupertino, California, Durect Corp. continues to pursue innovation at the intersection of biotechnology and pharmaceuticals, playing a significant role in addressing critical health challenges globally.